Sanofi- Aspirion

A Phase 2a/b, randomized, double-blind, placebo-controlled,
parallel group study to investigate the efficacy and safety of
subcutaneous amlitelimab in adult patients with
non-responsive celiac disease as an adjunct to a gluten-free
diet     Study Details | NCT06557772 | A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease | ClinicalTrials.gov